Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Advanced Solid Neoplasm 2Solid Tumors 1Renal Insufficiency 1Neoplasm, Residual 1Melanoma 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumors 1Advanced Nonhematologic Malignancies 1

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors × pevonedistat × Clear all
NCT01862328 2020-06-22

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Takeda

Phase 1 Completed
64 enrolled 21 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡